COVID-19: an Update on Diagnostic and Therapeutic Approaches

Overview

Journal BMB Rep

Specialties Biochemistry
Molecular Biology

Date 2020 Apr 28

PMID 32336317

Citations 35

Authors

Mahalaxmi Iyer

Kaavya Jayaramayya

Mohana Devi Subramaniam

Soo Bin Lee

Ahmed Abdal Dayem

Ssang-Goo Cho

Balachandar Vellingiri

Affiliations

Soon will be listed here.

Abstract

The unexpected pandemic set off by the novel coronavirus 2019 (COVID-19) has caused severe panic among people worldwide. COVID-19 has created havoc, and scientists and physicians are urged to test the efficiency and safety of drugs used to treat this disease. In such a pandemic situation, various steps have been taken by the government to control and prevent the Severe Acute Respiratory Syndrome coronavirus 2 (SARSCoV- 2). This pandemic situation has forced scientists to rework strategies to combat infectious diseases through drugs, treatment, and control measures. COVID-19 treatment requires both limiting viral multiplication and neutralizing tissue damage induced by an inappropriate immune reaction. Currently, various diagnostic kits to test for COVID-19 are available, and repurposing therapeutics for COVID-19 has shown to be clinically effective. As the global demand for diagnostics and therapeutics continues to rise, it is essential to rapidly develop various algorithms to successfully identify and contain the virus. This review discusses the updates on specimens/samples, recent efficient diagnostics, and therapeutic approaches to control the disease and repurposed drugs mainly focusing on chloroquine/hydroxychloroquine and convalescent plasma (CP). More research is required for further understanding of the influence of diagnostics and therapeutic approaches to develop vaccines and drugs for COVID-19. [BMB Reports 2020; 53(4): 191-205].

Citing Articles

Performance of protein N linear epitopes in serodiagnosis of COVID-19 infection.

Farajnia S, Khajenasiri N, Farajnia S, Seyrafi F, Bakhtiyari N Bioimpacts. 2025; 15:30232.

PMID: 39963569 PMC: 11830139. DOI: 10.34172/bi.30232.

Nanomaterials-assisted gene editing and synthetic biology for optimizing the treatment of pulmonary diseases.

Lei L, Pan W, Shou X, Shao Y, Ye S, Zhang J J Nanobiotechnology. 2024; 22(1):343.

PMID: 38890749 PMC: 11186260. DOI: 10.1186/s12951-024-02627-w.

Light-Based Therapy: Novel Approach to Treat COVID-19.

Azadeh S, Esmaeeli Djavid G, Nobari S, Keshmiri Neghab H, Rezvan M Tanaffos. 2024; 22(3):279-289.

PMID: 38638386 PMC: 11022193.

Sensitivity of nasopharyngeal swab and saliva specimens in the detection of SARS-CoV-2 virus among boarding school girls.

Devina C, Nasution B, Kusumawati R, Daulay R, Trisnawati Y, Lubis I IJID Reg. 2023; .

PMID: 37363192 PMC: 10157386. DOI: 10.1016/j.ijregi.2023.02.009.

Is the post-COVID-19 syndrome a severe impairment of acetylcholine-orchestrated neuromodulation that responds to nicotine administration?.

Leitzke M Bioelectron Med. 2023; 9(1):2.

PMID: 36650574 PMC: 9845100. DOI: 10.1186/s42234-023-00104-7.

References

Hung I, To K, Lee C, Lee K, Chan K, Yan W . Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011; 52(4):447-56. PMC: 7531589. DOI: 10.1093/cid/ciq106. View

Gao J, Tian Z, Yang X . Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020; 14(1):72-73. DOI: 10.5582/bst.2020.01047. View

Mair-Jenkins J, Saavedra-Campos M, Baillie J, Cleary P, Khaw F, Lim W . The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2014; 211(1):80-90. PMC: 4264590. DOI: 10.1093/infdis/jiu396. View

Cheng Z, Lu Y, Cao Q, Qin L, Pan Z, Yan F . Clinical Features and Chest CT Manifestations of Coronavirus Disease 2019 (COVID-19) in a Single-Center Study in Shanghai, China. AJR Am J Roentgenol. 2020; 215(1):121-126. DOI: 10.2214/AJR.20.22959. View

Zheng F, Tang W, Li H, Huang Y, Xie Y, Zhou Z . Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha. Eur Rev Med Pharmacol Sci. 2020; 24(6):3404-3410. DOI: 10.26355/eurrev_202003_20711. View

Cao J, Tu W, Cheng W, Yu L, Liu Y, Hu X . Clinical Features and Short-term Outcomes of 102 Patients with Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis. 2020; 71(15):748-755. PMC: 7184479. DOI: 10.1093/cid/ciaa243. View

Chen L, Xiong J, Bao L, Shi Y . Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020; 20(4):398-400. PMC: 7128218. DOI: 10.1016/S1473-3099(20)30141-9. View

Ko J, Seok H, Cho S, Ha Y, Baek J, Kim S . Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. Antivir Ther. 2018; 23(7):617-622. DOI: 10.3851/IMP3243. View

Callaway E, Cyranoski D . China coronavirus: Six questions scientists are asking. Nature. 2020; 577(7792):605-607. DOI: 10.1038/d41586-020-00166-6. View

10.

Zhou B, Zhong N, Guan Y . Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med. 2007; 357(14):1450-1. DOI: 10.1056/NEJMc070359. View

11.

Wang L, Wang Y, Ye D, Liu Q . Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence. Int J Antimicrob Agents. 2020; 55(6):105948. PMC: 7156162. DOI: 10.1016/j.ijantimicag.2020.105948. View

12.

Gautret P, Lagier J, Parola P, Hoang V, Meddeb L, Mailhe M . RETRACTED: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020; 56(1):105949. PMC: 7102549. DOI: 10.1016/j.ijantimicag.2020.105949. View

13.

Cao Y, Liu X, Xiong L, Cai K . Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2: A systematic review and meta-analysis. J Med Virol. 2020; 92(9):1449-1459. PMC: 7228215. DOI: 10.1002/jmv.25822. View

14.

Ducharme J, Farinotti R . Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. Clin Pharmacokinet. 1996; 31(4):257-74. DOI: 10.2165/00003088-199631040-00003. View

15.

Lee P, Hsueh P . Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV. J Microbiol Immunol Infect. 2020; 53(3):365-367. PMC: 7102579. DOI: 10.1016/j.jmii.2020.02.001. View

16.

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M . Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3):269-271. PMC: 7054408. DOI: 10.1038/s41422-020-0282-0. View

17.

Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P . In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020; 71(15):732-739. PMC: 7108130. DOI: 10.1093/cid/ciaa237. View

18.

Vellingiri B, Jayaramayya K, Iyer M, Narayanasamy A, Govindasamy V, Giridharan B . COVID-19: A promising cure for the global panic. Sci Total Environ. 2020; 725:138277. PMC: 7128376. DOI: 10.1016/j.scitotenv.2020.138277. View

19.

Devaux C, Rolain J, Colson P, Raoult D . New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?. Int J Antimicrob Agents. 2020; 55(5):105938. PMC: 7118659. DOI: 10.1016/j.ijantimicag.2020.105938. View

20.

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054-1062. PMC: 7270627. DOI: 10.1016/S0140-6736(20)30566-3. View